Postoperative gemcitabine alone and concurrent with radiation therapy in locally advanced pancreatic carcinoma

Basit Öğe Kaydı
dc.contributor.authorOzkok, Serdar
dc.contributor.authorDemirci, Senem
dc.contributor.authorYalman, Deniz
dc.contributor.authorZeytunlu, Murat
dc.contributor.authorNart, Deniz
dc.contributor.authorYuzer, Yildiray
dc.contributor.authorCoker, Ahmet
dc.contributor.authorGoker, Erdem
dc.date.accessioned2019-10-27T21:16:50Z
dc.date.available2019-10-27T21:16:50Z
dc.date.issued2010
dc.departmentEge Üniversitesien_US
dc.description.abstractAims and background. To evaluate the treatment results of gemcitabine alone and concurrent with radiotherapy after R0/R1 resection of locally advanced pancreatic cancer. Methods and study design. From 1999 to 2005, 55 patients with stage II resected pancreatic cancer treated with gemcitabine-based radiochemotherapy were retrospectively evaluated. Initially, one cycle of induction gemcitabine was administered and followed by weekly gemcitabine concurrent with radiotherapy. After the completion of radiochemotherapy, patients received 3 additional courses of gemcitabine. Results. Thirteen patients were stage IIA and 42 were stage JIB. Forty-six patients (83.6%) had RO and 9 patients (16.4%) had R1 resection. All of the patients received induction chemotherapy and radiotherapy, all but 3 received concurrent radiochemotherapy, and 46 (84%) patients received maintenance chemotherapy. During induction, concurrent and maintenance phases of the protocol, 11%, 13.5% and 19.5% of the patients had at least one grade 3 toxicity, respectively. Within a median 47 months (range, 34-105) of follow-up, 4 (7.3%) patients had isolated local recurrence, 5 (9%) patients had local recurrence and distant metastases, and 27 (49%) had only distant metastases. Median disease-free survival and overall survival were 13 (range, 4-105) and 19 months (range, 6-105), respectively. In multivariate analysis, nodal stage, AJCC stage and number of lymph nodes dissected were the significant factors affecting disease-free survival whereas Karnofsky performance status was the only significant factor for overall survival. Conclusions. The prognosis for pancreatic cancer remains poor despite adjuvant radiochemotherapy. More aggressive treatments should be considered in patients with unfavorable prognostic factors. Free full text available at www.tumorionline.iten_US
dc.identifier.endpage567en_US
dc.identifier.issn0300-8916
dc.identifier.issn2038-2529
dc.identifier.issue4en_US
dc.identifier.pmid20968135en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage560en_US
dc.identifier.urihttps://hdl.handle.net/11454/43728
dc.identifier.volume96en_US
dc.identifier.wosWOS:000284187400008en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofTumori Jen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectgemcitabineen_US
dc.subjectpancreatic canceren_US
dc.subjectpostoperative radiochemotherapyen_US
dc.subjectprognostic factorsen_US
dc.titlePostoperative gemcitabine alone and concurrent with radiation therapy in locally advanced pancreatic carcinomaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu